Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Higher Potency Zoster Vaccine in Adults 50+
NCT00092417Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2003
- Primary completion
- Jun 2004
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, double-blind trial of varicella virus vaccine live in herpes zoster (HZ) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With Vaccine-related Serious Clinical Adverse Experiences and Number of Participants With Moderate or Severe Injection-site Pain/Tenderness/Soreness or Swelling. Started Oct 2003; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00092417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092417.